Bioventus (BVS)

• Market cap: $439M
• 1 day: -1.34%
• 5 days: -1.93%
• 1 month: 1.22%
• 3 months: -31.11%
• 6 months: -39.98%
• Year to date: -37.72%
• 1 year: 1.22%
• 5 years: -65.54%
• 10 years: -65.54%
• Sector: Healthcare
• Industry: Medical Devices

About: Bioventus Inc is a medical technology company. The company is engaged in developing and commercializing clinically differentiated treatments that engage and enhance the body's natural healing process. It offers a diverse portfolio of products to serve physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine and neurosurgery. Its portfolio of products is grouped into three verticals based on clinical use: Pain Treatments, Surgical Solutions, and Restorative Therapies. Geographical presence is in the United States which derives key revenue, and International markets.

Employees: 930

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

126% more call options, than puts

Call options by funds: $823K | Put options by funds: $364K

17% more repeat investments, than reductions

Existing positions increased: 55 | Existing positions reduced: 47

1.68% more ownership

Funds ownership: 69.62% [Q4 2024] → 71.31% (+1.68%) [Q1 2025]

0% more funds holding in top 10

Funds holding in top 10: 3 [Q4 2024] → 3 (+0) [Q1 2025]

4% less funds holding

Funds holding: 151 [Q4 2024] → 145 (-6) [Q1 2025]

6% less capital invested

Capital invested by funds: $478M [Q4 2024] → $448M (-$29.6M) [Q1 2025]

18% less first-time investments, than exits

New positions opened: 18 | Existing positions closed: 22

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $15 127% upside
• Avg. target: $15 127% upside
• High target: $15 127% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

Canaccord Genuity Caitlin Cronin

127% upside $15

Buy Maintained

17 Mar 2025